Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
3,54 USD | +1,72 % | +14,19 % | -19,55 % |
Resumen de negocios
Número de empleados: 17
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Stephen Brady
CEO | Chief Executive Officer | 54 | 01/09/19 |
Nicholas Maestas
DFI | Director of Finance/CFO | 44 | 12/07/21 |
Darrin Bomba
CTO | Chief Tech/Sci/R&D Officer | - | 01/12/21 |
Sam Whiting
CTO | Chief Tech/Sci/R&D Officer | 58 | 01/11/20 |
Comptroller/Controller/Auditor | 36 | 01/06/22 | |
Sharon Sakai
LAW | General Counsel | - | - |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Director/Board Member | 56 | 01/07/21 | |
Geoffrey Nichol
BRD | Director/Board Member | 69 | 01/12/19 |
Mike Raab Raab
CHM | Chairman | 59 | 01/01/21 |
Ronit Simantov
BRD | Director/Board Member | 59 | 06/08/21 |
Stephen Brady
CEO | Chief Executive Officer | 54 | 01/09/19 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 22 217 265 | 22 203 364 ( 99,94 %) | 0 | 99,94 % |
Información de la empresa
Tempest Therapeutics, Inc.
2000 Sierra Point Parkway Suite 400
94005, Brisbane
+
http://www.tempesttx.comSector
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
-19,55 % | 78,65 M | |
+1,51 % | 42,75 mil M | |
+8,57 % | 41,34 mil M | |
+49,22 % | 41,61 mil M | |
-12,36 % | 26,59 mil M | |
+8,92 % | 25,49 mil M | |
-25,13 % | 18,12 mil M | |
+29,17 % | 12,24 mil M | |
-3,12 % | 11,76 mil M | |
+6,35 % | 11 mil M |
- Bolsa de valores
- Acciones
- Acción TPST
- Empresa Tempest Therapeutics, Inc.